AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow

AbbVie Inc. (NYSE:ABBV) is included among the 10 Best Quality Dividend Stocks to Buy According to Reddit.

AbbVie Inc. (NYSE:ABBV) is a global biopharma company built around research and a fairly broad mix of treatments. It develops and sells drugs across areas like immunology, oncology, aesthetics, neuroscience, and eye care, along with a few other categories.

The stock is struggling this year, falling by more than 13% so far in 2026. On the surface, that might suggest pressure. But the company’s financial position doesn’t really reflect a business in trouble. A big part of that stability comes from how AbbVie has reshaped its portfolio. Skyrizi and Rinvoq have gradually taken over as the core growth drivers in immunology. At this point, those two drugs are bringing in more revenue combined than Humira ever did on its own.

In 2025, Skyrizi generated $17.6 billion in sales, while Rinvoq contributed $8.3 billion. That puts the total at $25.9 billion. Humira’s peak, by comparison, was $21.2 billion in 2022.

Dividends are another area where AbbVie stands out. The company is considered a Dividend King, with 54 straight years of dividend increases when including its time under Abbott Laboratories. It raised the payout again this year by 5.4% to $1.73 per share. The continued growth of Skyrizi and Rinvoq, along with progress in its oncology business, is helping support free cash flow. That, in turn, gives the company room to keep increasing its dividend over time.

READ NEXT: 10 Best May Dividend Stocks to Buy and 10 Best Dividend Stocks Yielding at Least 7% According to Hedge Funds

Disclosure: None. Follow Insider Monkey on Google News.